Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR4 | P61073 | 3/20 | 0.50 |
| ▸ | HRH1 | P35367 | 2/20 | 0.50 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | LIN28A | Q9H9Z2 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.50 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.50 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.50 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.50 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.43 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.43 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.43 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.43 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.43 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.43 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.43 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.43 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2474794 | 1.00 | CXCR4 (0.50) | CXCR4HRH1CHRM2MAPTSMN1; SMN2 | |
| SCHEMBL3929940 | 0.95 | SMN1; SMN2 (0.53) | CXCR4HRH1CHRM2MAPTSMN1; SMN2 | |
| SCHEMBL8507962 | 0.89 | SMN1; SMN2 (0.56) | HRH1MAPTSMN1; SMN2LIN28ATDP1 | |
| SCHEMBL12453816 | 0.89 | SMN1; SMN2 (0.59) | MAPTSMN1; SMN2LIN28ATDP1HDAC1 | |
| SCHEMBL8208011 | 0.86 | SMN1; SMN2 (0.60) | MAPTSMN1; SMN2LIN28ATDP1HDAC1 | |
| SCHEMBL8211406 | 0.86 | SMN1; SMN2 (0.60) | MAPTSMN1; SMN2LIN28ATDP1HDAC1 | |
| SCHEMBL2831556 | 0.86 | MAPT (0.68) | CXCR4HRH1CHRM2MAPTSMN1; SMN2 | |
| SCHEMBL2818579 | 0.86 | SMN1; SMN2 (0.68) | MAPTSMN1; SMN2LIN28ATDP1HDAC1 | |
| SCHEMBL13764390 | 0.86 | MAPT (0.68) | CXCR4HRH1CHRM2MAPTSMN1; SMN2 | |
| SCHEMBL13797705 | 0.85 | SMN1; SMN2 (0.48) | MAPTSMN1; SMN2LIN28ATDP1HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8440841-B2 | 5-pyrrolidinylsulfonyl isatin derivatives | Universitätsklinikum Münster (DE) | 2013-05-14 | — | — | US | disclosed |
| US-20090041664-A1 | 5-Pyrrolidinylsulfonyl Isatin Derivatives | UNIVERSITATSKLINIKUM MUNSTER (DE) | 2009-02-12 | — | — | US | disclosed |
| EP-1682113-B1 | INHIBITOR IMAGING AGENTS | GE HEALTHCARE LTD (GB) | 2008-01-23 | — | — | EP | disclosed |
| EP-1841759-A2 | 5-PYRROLIDINYLSULFONYL ISATIN DERIVATIVES | Universitätsklinikum Münster (DE) | 2007-10-10 | — | — | EP | disclosed |
| US-20070184537-A1 | Method for the linkage of bifunctional chelating agents and (radioactive) transition metal complexes to proteins and peptides | PAUL SCHERRER INSTITUT (CH) | 2007-08-09 | — | — | US | disclosed |
| US-20070104644-A1 | Inhibitor imaging agents | CUTHBERTSON ALAN | 2007-05-10 | — | — | US | disclosed |
| CN-1901894-A | Inhibitor imaging agents | GE HEALTHCARE LTD (GB) | 2007-01-24 | — | — | CN | disclosed |
| EP-1682113-A1 | INHIBITOR IMAGING AGENTS | GE Healthcare Limited (GB) | 2006-07-26 | — | — | EP | disclosed |
| WO-2006074799-A2 | 5-PYRROLIDINYLSULFONYL ISATIN DERIVATIVES | Universitätsklinikum Münster (DE) | 2006-07-20 | — | — | WO | disclosed |
| WO-2005049005-A1 | INHIBITOR IMAGING AGENTS | GE HEALTHCARE LIMITED (GB) | 2005-06-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090041664-A1 | 5-Pyrrolidinylsulfonyl Isatin Derivatives | CASP5, CTSZ, CTSS | CXCR4 926/4885HRH1 2593/4885CHRM2 4858/4885 |
| US-20070184537-A1 | Method for the linkage of bifunctional chelating agents and (radioactive) transition metal complexes to proteins and peptides | EPRS1, SLC7A11, QPCTL | CXCR4 3859/4885HRH1 2813/4885CHRM2 4370/4885 |
| US-20070104644-A1 | Inhibitor imaging agents | MMP3, MMP1, MMP10 | CXCR4 2982/4885HRH1 3306/4885CHRM2 4657/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.